UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

The Lancet (British edition), 2023-04, Vol.401 (10386), p.1427-1437

2023

Volltextzugriff (PDF)

S303: A PHASE 3 STUDY (ATLAS‐PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS

HemaSphere, 2023-08, Vol.7 (S3), p.e643526e-n/a

2023

Volltextzugriff (PDF)

Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2

Journal of thrombosis and haemostasis, 2020-09, Vol.18 (S1), p.5-14

2020

Volltextzugriff (PDF)

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood, 2024-05, Vol.143 (22), p.2256-2269

2024

Volltextzugriff (PDF)

Phase 3 Trial of Concizumab in Hemophilia with Inhibitors

The New England journal of medicine, 2023-08, Vol.389 (9), p.783-794

2023

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics of a next‐generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients

Journal of thrombosis and haemostasis, 2021-04, Vol.19 (4), p.967-975

2021

Volltextzugriff (PDF)

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial

The Lancet. Haematology, 2023-05, Vol.10 (5), p.e322-e332

2023

Volltextzugriff (PDF)

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A

Blood Research, 2019, 54(3), , pp.204-209

2019

Volltextzugriff (PDF)

Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years

Blood Research, 2021, 56(3), , pp.141-149

2021

Volltextzugriff (PDF)

Clinical data on treatment regimen and use of medication among patients with hemophilia B in Korea

Blood Research, 2024, 59(3), , pp.27-27

2024

Volltextzugriff (PDF)

Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array

Haematologica (Roma), 2012-02, Vol.97 (2), p.304-309

2012

Volltextzugriff (PDF)

Mutation analysis of factor VIII in Korean patients with severe hemophilia A

International journal of hematology, 2010-06, Vol.91 (5), p.784-791

2010

Volltextzugriff (PDF)

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients

Blood Research, 2019, 54(3), , pp.198-203

2019

Volltextzugriff (PDF)

A pediatric case of idiopathic Harlequin syndrome

Korean journal of pediatrics, 2016-11, Vol.59 (Suppl 1), p.S125

2016

Volltextzugriff (PDF)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea

Korean journal of pediatrics, 2013-07, Vol.56 (7), p.291

2013

Volltextzugriff (PDF)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea

Korean journal of pediatrics, 2013, Vol.56 (7), p.291-297

2013

Volltextzugriff (PDF)

A pediatric case of idiopathic Harlequin syndrome

Korean journal of pediatrics, 2016, Vol.59 (1), p.125-128

2016

Volltextzugriff (PDF)

Effects of thyroxine on hyperkalemia and renal cortical Na+, K+ - ATPase activity induced by cyclosporin A

Journal of Korean medical science, 2002-10, Vol.17 (5), p.625-632

2002

Volltextzugriff (PDF)

Active Lifestyle in Patients with Hemophilia A or B with Inhibitors on Once-Daily Subcutaneous Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

Blood, 2022-11, Vol.140 (Supplement 1), p.5634-5636

2022

Volltextzugriff (PDF)

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Blood, 2021-12, Vol.138 (Supplement 2), p.LBA-3-LBA-3

2021

Volltextzugriff (PDF)

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Thrombosis and haemostasis, 2017, Vol.117 (2), p.252-261

2017

Volltextzugriff (PDF)

Reticulocyte hemoglobin content for the diagnosis of iron deficiency in young children with acute infection

Korean journal of pediatrics, 2008, Vol.51 (8), p.827

2008

Volltextzugriff (PDF)

Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Activity

Blood, 2017-12, Vol.130 (Suppl_1), p.87-87

2017

Volltextzugriff (PDF)

Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B

Blood, 2014-12, Vol.124 (21), p.1523-1523

2014

Volltextzugriff (PDF)

The Value of Preoperative Coagulation Screening in Children Undergoing Surgery

Korean journal of hematology, 2008, Vol.43 (2), p.98

2008

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(34)
Tagungsberichte
(1)

Sprache

Englisch
(29)
Koreanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

S303: A PHASE 3 STUDY (ATLAS‐PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS

Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Phase 3 Trial of Concizumab in Hemophilia with Inhibitors

Safety, pharmacokinetics, and pharmacodynamics of a next‐generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A

Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years

Clinical data on treatment regimen and use of medication among patients with hemophilia B in Korea

Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array

Mutation analysis of factor VIII in Korean patients with severe hemophilia A

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients

A pediatric case of idiopathic Harlequin syndrome

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea

A pediatric case of idiopathic Harlequin syndrome

Effects of thyroxine on hyperkalemia and renal cortical Na+, K+ - ATPase activity induced by cyclosporin A

Active Lifestyle in Patients with Hemophilia A or B with Inhibitors on Once-Daily Subcutaneous Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Reticulocyte hemoglobin content for the diagnosis of iron deficiency in young children with acute infection

Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Activity

Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B

The Value of Preoperative Coagulation Screening in Children Undergoing Surgery

Suchergebnisse filtern